Retrospective Analysis of Lipid-Lowering and Antiplatelet Therapy Regimen by Clinical Decision Support Service Based

K S Benimetskaya1, S I Provatorov2, M V Ezhov2

  • 1Zelman Institute of Medicine and Psychology, Novosibirsk State University, Novosibirsk.

Kardiologiia
|December 13, 2023
PubMed

Insights

Clinical decision support services (CDSS) significantly altered lipid-lowering and antithrombotic therapy recommendations compared to electronic medical records. This suggests CDSS can enhance cardiovascular complication prevention strategies.

Area of Science:

  • Cardiology
  • Medical Informatics

Background:

  • Cardiovascular disease prevention relies heavily on appropriate lipid-lowering and antithrombotic therapies.
  • Clinical decision support services (CDSS) offer potential to optimize therapeutic choices.

Purpose of the Study:

  • To evaluate the prescription patterns of lipid-lowering and antithrombotic therapy in clinical practice.
  • To compare these prescriptions with recommendations generated by a CDSS.

Main Methods:

  • Retrospective analysis of 292 patients' electronic medical records (EMR) from August to December 2022.
  • Comparison of EMR-documented therapies with CDSS guidelines under expert supervision.
  • Primary endpoint: change in prescribed therapy based on CDSS recommendations.

Main Results:

  • Significant differences were observed between CDSS recommendations and EMR prescriptions for both lipid-lowering and antithrombotic therapies.
  • Lipid-lowering therapy differed in 50% of primary prevention and 78.9% of secondary prevention patients.
  • Antithrombotic therapy recommendations from CDSS differed in 76.8% of patients.

Conclusions:

  • The implementation of CDSS demonstrated a substantial impact on therapeutic choices for lipid-lowering and antithrombotic agents.
  • CDSS holds promise for improving the selection of these therapies, potentially reducing cardiovascular complications.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
667
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
843
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
728
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708